Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660173 · ClinicalTrials.gov registry record · Phase 2
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
A Phase 2 study of Type 2 Diabetes Mellitus (T2DM), sponsored by Amgen.
- Active
- Registry status
- Phase 2
- Development phase
- 409
- Enrollment target
- 20
- Study locations
NCT06660173 is a Phase 2 study of Type 2 Diabetes Mellitus (T2DM) that is active but no longer recruiting, run by Amgen. The registered enrollment target is 409 participants, below the 505-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06660173, a Phase 2 study of Type 2 Diabetes Mellitus (T2DM), is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 409 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart Cafraglutide
Study Locations (20)
California
- Anaheim Clinical Trials - Anaheim
- Hope Clinical Research LLC - Canoga Park
- Orange County Research Center - Lake Forest
- San Jose Clinical Trials - San Jose
Florida
- Northeast Research Institute - Neri - Fleming Island
- New Horizon Research Center - Miami
- Florida Institute for Clinical Research - Orlando
- Conquest Research - Winter Park - Winter Park
Texas
- FutureSearch Trials of Neurology - Austin
- Velocity Clinical Research - Dallas - Dallas
Alabama
- Accel Research Site - Birmingham Clinical Research Unit - Birmingham
Georgia
- Accel Research Site - Neurostudies - Decatur
Illinois
- Cedar Crosse Research and Health Care - Chicago
Louisiana
- Tandem Clinical Research - Marrero - Marrero
Michigan
- DM Clinical - Detroit - Southfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2024-11-07 |
| Est. Completion | 2026-11-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06660173
The ClinicalTrials.gov registry entry for NCT06660173 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 505-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (19% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06660173 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06660173 about?
NCT06660173 is a clinical study titled "A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)". The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
What is the current status of trial NCT06660173?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 409 participants. The study started on 2024-11-07. Estimated completion is 2026-11-10.
What conditions does trial NCT06660173 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM).
What interventions are being tested in trial NCT06660173?
The interventions under investigation include: Placebo (DRUG), Maridebart Cafraglutide (DRUG).
Who is sponsoring clinical trial NCT06660173?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660173 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
ACTIVE NOT RECRUITING · Phase 2
-
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
ACTIVE NOT RECRUITING · Phase 2
-
Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.